Systematic ligand binding assay (LBA) method development and optimization strategy

This webinar compares and discusses different approaches that can be used to assess key assay parameters for PK and biomarker LBAs, as well as the advantages and disadvantages of each approach. This webinar also summarizes a systematic approach to guide LBA method development and optimization with a suggested way to interpret parallelism data.

What will you learn?

  • Background and challenges for LBA method development
  • Parallelism experiment and parallelism data interpretation
  • Systematic LBA method development and optimization strategy

Who may this interest?

  • Bioanalysis professionals
  • Bioanalysis field- related graduate students
  • Quality unit professionals
  • Regulatory agents



Jing Tu

Senior Group Leader

PPD® Laboratories


Jing Tu has been working in the CRO and pharmaceutical industry since 2011. She started her career with Frontage Laboratories (PA, USA) in its US biologics ligand binding services lab. As a Frontage scientist, she was then selected by Janssen R&D (NJ, USA) (formerly Centocor) to work within their ligand binding laboratories. In 2015, Jing joined PPD Laboratories’ (VA, USA) biomarker lab and started its biomarker ligand binding assay (LBA) group. Jing has led the integration of new technologies into the lab and also implemented a systematic LBA biomarker method development strategy.

About the Bioanalysis Rising Star Award

The Bioanalysis Rising Star Award (formerly the New Investigator Award) is an annual prestigious award recognizing the most promising early-career scientists in the field of bioanalysis. Sponsored by Waters Corporation (MA, USA), our vision is to promote the work of highly talented researchers offering a springboard to help establish themselves in the exciting world of bioanalysis.






In association with

waters 150x80